MEDIVIR AB based in Huddinge, SE has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2024-09-19 ✅ Patent 12,479,870 granted on 2025-11-25

US20240309031A1

Chemistry; metallurgy

Base-Modified Cytidine Nucleotides for Leukemia Therapy

#2 | 2024-01-25

US20240024342A1

Human necessities

MIV-818/LENVATINIB COMBINATION THERAPY FOR LIVER CANCER

#3 | 2023-05-18 ✅ Patent 11,951,147 granted on 2024-04-09

US20230149500A1

Human necessities

SMAC mimetic

#4 | 2022-10-20 ✅ Patent 12,378,209 granted on 2025-08-05

US20220332690A1

Chemistry; metallurgy

PROTEASE INHIBITORS

#5 | 2021-01-21 ✅ Patent 11,312,693 granted on 2022-04-26

US20210017140A1

Chemistry; metallurgy

Protease inhibitors

#6 | 2020-12-24 ✅ Patent 12,221,459 granted on 2025-02-11

US20200399295A1

Chemistry; metallurgy

Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides

#7 | 2020-09-10 ✅ Patent 11,351,221 granted on 2022-06-07

US20200282002A1

Human necessities

SMAC mimetic

#8 | 2020-01-09 ✅ Patent 10,723,709 granted on 2020-07-28

US20200010434A1

Chemistry; metallurgy

Protease inhibitors

#9 | 2019-08-22 ✅ Patent 10,596,220 granted on 2020-03-24

US20190255139A1

Human necessities

SMAC mimetic

#10 | 2018-11-15 ✅ Patent 10,329,266 granted on 2019-06-25

US20180327371A1

Chemistry; metallurgy

Protease inhibitors

#11 | 2018-10-25 ✅ Patent 10,314,881 granted on 2019-06-11

US20180303897A1

Human necessities

SMAC mimetic

#12 | 2017-12-21 ✅ Patent 10,258,595 granted on 2019-04-16

US20170360741A1

Human necessities

Pharmaceutical formulation for histone deacetylase inhibitors

#13 | 2017-08-10 ✅ Patent 9,856,265 granted on 2018-01-02

US20170226111A1

Chemistry; metallurgy

Macrocyclic inhibitors of hepatitis C virus

#14 | 2017-07-13 ✅ Patent 10,172,846 granted on 2019-01-08

US20170196849A1

Human necessities

HCV NS-3 serine protease inhibitors

#15 | 2016-11-24 ✅ Patent 9,540,411 granted on 2017-01-10

US20160340380A1

Chemistry; metallurgy

HCV polymerase inhibitors

#16 | 2016-08-18 ✅ Patent 9,623,022 granted on 2017-04-18

US20160235737A1

Human necessities

Macrocyclic inhibitors of hepatitis C virus

#17 | 2016-07-07 ✅ Patent 9,650,388 granted on 2017-05-16

US20160194334A1

Chemistry; metallurgy

Form 2 crystalline polymorph of a salt of N-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-B]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazinyl) thiazol-4-yl]-benzamide useful as cysteine protease inhibitor

#18 | 2016-03-10 ✅ Patent 9,428,517 granted on 2016-08-30

US20160068539A1

Chemistry; metallurgy

Protease inhibitors

#19 | 2015-08-06 ✅ Patent 9,353,103 granted on 2016-05-31

US20150218153A1

Chemistry; metallurgy

Macrocyclic inhibitors of hepatitis C virus

#20 | 2014-09-11 ✅ Patent 9,040,562 granted on 2015-05-26

US20140255347A1

Chemistry; metallurgy

Macrocyclic inhibitors of hepatitis C virus

#21 | 2014-08-07 ✅ Patent 9,200,006 granted on 2015-12-01

US20140221654A1

Chemistry; metallurgy

Protease inhibitors

#22 | 2014-03-06

US20140066398A1

Chemistry; metallurgy

HCV POLYMERASE INHIBITORS

#23 | 2013-09-19 ✅ Patent 9,012,428 granted on 2015-04-21

US20130244968A1

Chemistry; metallurgy

Uracyl spirooxetane nucleoside phosphoramidates

#24 | 2013-09-05 ✅ Patent 8,735,395 granted on 2014-05-27

US20130231349A1

Chemistry; metallurgy

Protease inhibitors

#25 | 2013-08-29 ✅ Patent 9,006,209 granted on 2015-04-14

US20130225520A1

Chemistry; metallurgy

Uracyl spirooxetane nucleoside phosphoramidates

#26 | 2013-08-22 ✅ Patent 8,754,106 granted on 2014-06-17

US20130217725A1

Human necessities

Macrocyclic inhibitors of hepatitis C virus

#27 | 2013-08-22 ✅ Patent 8,933,052 granted on 2015-01-13

US20130217648A1

Chemistry; metallurgy

Uracyl spirooxetane nucleosides

#28 | 2013-08-22

US20130217646A1

Human necessities

COMBINATION OF ALOVUDINE AND ZIDOVUDINE IN A MOLAR RATIO OF 1:100 TO 1:350

#29 | 2013-06-06

US20130143835A1

Chemistry; metallurgy

HCV Polymerase Inhibitors

#30 | 2013-04-11 ✅ Patent 8,741,926 granted on 2014-06-03

US20130089520A1

Human necessities

Macrocyclic inhibitors of hepatitis C virus

#31 | 2013-01-31

US20130028865A1

Human necessities

Combination of a Macrocyclic Inhibitor of HCV, A Non-Nucleoside and a Nucleoside

#32 | 2012-11-15 ✅ Patent 8,426,421 granted on 2013-04-23

US20120289519A1

Chemistry; metallurgy

Protease inhibitors

#33 | 2012-09-06 ✅ Patent 8,552,021 granted on 2013-10-08

US20120225839A1

Chemistry; metallurgy

Phosphoramidate derivatives of nucleosides

#34 | 2012-08-30 ✅ Patent 8,466,158 granted on 2013-06-18

US20120220602A1

Chemistry; metallurgy

Cysteine protease inhibitors

#35 | 2012-07-05 ✅ Patent 8,349,869 granted on 2013-01-08

US20120171157A1

Chemistry; metallurgy

Macrocylic inhibitors of hepatitis C virus

#36 | 2012-05-17

US20120123119A1

Chemistry; metallurgy

ACYCLIC NUCLEOSIDE DERIVATIVES

#37 | 2012-05-10

US20120115807A1

Human necessities

COMBINATION OF ALOVUDINE AND ZIDOVUDINE IN A MOLAR RATIO OF 1:100 TO 1:350

#38 | 2012-03-15 ✅ Patent 8,481,510 granted on 2013-07-09

US20120065156A1

Chemistry; metallurgy

Uracyl spirooxetane nucleosides

#39 | 2012-01-19 ✅ Patent 8,338,471 granted on 2012-12-25

US20120015994A1

Chemistry; metallurgy

(2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors

#40 | 2011-09-22 ✅ Patent 8,399,429 granted on 2013-03-19

US20110230436A1

Chemistry; metallurgy

Uracyl cyclopropyl nucleotides

#41 | 2011-07-14 ✅ Patent 8,158,779 granted on 2012-04-17

US20110172410A1

Chemistry; metallurgy

Antiviral nucleosides

#42 | 2011-05-12 ✅ Patent 8,143,396 granted on 2012-03-27

US20110112294A1

Chemistry; metallurgy

1-[2′, 3′ -dideoxy-3′ C- (hydroxymethyl)—beta-D-erythro-pentofuranosyl] cytosine derivatives as HIV inhibitors

#43 | 2011-05-12

US20110112089A1

Chemistry; metallurgy

Cysteine Protease Inhibitors

#44 | 2011-05-05 ✅ Patent 8,198,283 granted on 2012-06-12

US20110105524A1

Chemistry; metallurgy

Cysteine protease inhibitors

#45 | 2011-04-21 ✅ Patent 8,431,588 granted on 2013-04-30

US20110092460A1

Chemistry; metallurgy

Cyclopropyl polymerase inhibitors

#46 | 2011-02-17 ✅ Patent 8,242,119 granted on 2012-08-14

US20110039862A1

Chemistry; metallurgy

Protease inhibitors

#47 | 2011-01-27 ✅ Patent 8,017,620 granted on 2011-09-13

US20110021459A1

Human necessities

Dutpase inhibitors

#48 | 2011-01-20 ✅ Patent 7,935,681 granted on 2011-05-03

US20110015148A1

Chemistry; metallurgy

Antiviral nucleosides

#49 | 2010-07-01

US20100166706A1

Human necessities

HCV NS-3 SERINE PROTEASE INHIBITORS

#50 | 2010-05-27 ✅ Patent 7,825,239 granted on 2010-11-02

US20100130735A1

Chemistry; metallurgy

Antiviral nucleosides

#51 | 2010-05-06 ✅ Patent 8,937,080 granted on 2015-01-20

US20100113440A1

Chemistry; metallurgy

Pyrimidine substituted macrocyclic HCV inhibitors

#52 | 2010-03-25

US20100075924A1

Human necessities

DUTPASE INHIBITORS

#53 | 2010-01-07

US20100003216A1

Human necessities

HCV NS-3 Serine Protease Inhibitors

#54 | 2009-11-12 ✅ Patent 8,012,939 granted on 2011-09-06

US20090281141A1

Chemistry; metallurgy

Macrocyclic inhibitors of hepatitis C virus

#55 | 2009-11-12 ✅ Patent 8,148,399 granted on 2012-04-03

US20090281140A1

Chemistry; metallurgy

Macrocyclic inhibitors of hepatitis C virus

#56 | 2009-10-29

US20090270429A1

Human necessities

ANTIVIRAL FORMULATION

#57 | 2009-10-01 ✅ Patent 9,023,808 granted on 2015-05-05

US20090247512A1

Chemistry; metallurgy

Macrocyclic inhibitors of hepatitis C virus

#58 | 2009-08-27 ✅ Patent 8,022,092 granted on 2011-09-20

US20090215846A1

Chemistry; metallurgy

(2,5-dioxoimidazolidin-1-yl)-N-hydroxy-acetamides as metalloproteinase inhibitors

#59 | 2009-03-19 ✅ Patent 8,124,609 granted on 2012-02-28

US20090076041A1

Chemistry; metallurgy

Acyclic nucleoside derivatives

#60 | 2009-03-05 ✅ Patent 8,227,407 granted on 2012-07-24

US20090062311A1

Chemistry; metallurgy

Macrocyclic inhibitors of hepatitis C virus

#61 | 2009-01-22 ✅ Patent 7,700,552 granted on 2010-04-20

US20090023758A1

Chemistry; metallurgy

Macrocyclic inhibitors of hepatitis C virus

#62 | 2009-01-22 ✅ Patent 7,893,067 granted on 2011-02-22

US20090023748A1

Chemistry; metallurgy

Cysteine protease inhibitors

#63 | 2008-12-18 ✅ Patent 7,795,270 granted on 2010-09-14

US20080312183A1

Human necessities

DUTPase inhibitors

#64 | 2008-12-04 ✅ Patent 7,601,702 granted on 2009-10-13

US20080300216A1

Human necessities

Dutpase Inhibitors

#65 | 2008-10-09 ✅ Patent 7,807,677 granted on 2010-10-05

US20080249102A1

Chemistry; metallurgy

HIV protease inhibitors

#66 | 2008-10-07 ✅ Patent 7,432,274 granted on 2008-10-07

US10741615

Acyclic nucleoside derivatives

#67 | 2008-09-25 ✅ Patent 7,915,300 granted on 2011-03-29

US20080234260A1

Chemistry; metallurgy

Cysteine protease inhibitors

#68 | 2008-09-11 ✅ Patent 7,888,367 granted on 2011-02-15

US20080221140A1

Chemistry; metallurgy

1-[2′,3′ -dideoxy-3′ C-(hydroxymethyl)—beta-D-erythro-pentofuranosyl] cytosine derivatives as HIV

#69 | 2008-07-24 ✅ Patent 7,829,548 granted on 2010-11-09

US20080176817A1

Human necessities

Compounds useful in the treatment of HIV

#70 | 2008-06-26 ✅ Patent 7,666,856 granted on 2010-02-23

US20080152621A1

Chemistry; metallurgy

Antiviral nucleosides

#71 | 2008-03-20 ✅ Patent 7,915,295 granted on 2011-03-29

US20080070951A1

Chemistry; metallurgy

Non-nucleotide reverse transcriptase inhibitors

#72 | 2007-08-30 ✅ Patent 7,671,032 granted on 2010-03-02

US20070203072A1

Human necessities

HCV NS-3 serine protease inhibitors

#73 | 2007-07-12 ✅ Patent 7,608,590 granted on 2009-10-27

US20070161574A1

Human necessities

HCV NS-3 serine protease inhibitors

#74 | 2007-05-29 ✅ Patent 7,223,387 granted on 2007-05-29

US10334487

Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester

#75 | 2006-12-12 ✅ Patent 7,148,243 granted on 2006-12-12

US10243118

Antivirals

#76 | 2006-07-27 ✅ Patent 7,517,992 granted on 2009-04-14

US20060167055A1

Chemistry; metallurgy

Non-nucleoside reverse transcriptase inhibitors

#77 | 2006-06-08 ✅ Patent 7,825,238 granted on 2010-11-02

US20060122383A1

Chemistry; metallurgy

Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine

#78 | 2006-04-20

US20060084627A1

Human necessities

Synergistic interaction of abacavir and alovudine

#79 | 2006-03-16 ✅ Patent 7,071,173 granted on 2006-07-04

US20060058259A1

Chemistry; metallurgy

Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine

#80 | 2005-12-13 ✅ Patent 6,974,802 granted on 2005-12-13

US10015184

Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine

#81 | 2005-11-10 ✅ Patent 7,189,849 granted on 2007-03-13

US20050250795A1

Chemistry; metallurgy

Synthesis of acyclic nucleoside derivatives

#82 | 2005-10-27 ✅ Patent 7,405,310 granted on 2008-07-29

US20050240035A1

Chemistry; metallurgy

Non-nucleoside reverse transcriptase inhibitors

#83 | 2005-05-17 ✅ Patent 6,894,177 granted on 2005-05-17

US10377057

Intermediate compounds of non-nucleoside reverse transcriptase inhibitors

#84 | 2005-04-12 ✅ Patent 6,878,844 granted on 2005-04-12

US10315580

Synthesis of acyclic nucleoside derivatives

#85 | 2005-03-31

US20050070598A1

Chemistry; metallurgy

Cysteine protease inhibitors

Also check out MEDIVIR AB's (Huddinge, Sweden) applicant profile with 26 patent applications submitted.

AssigneeID:

7084 ⎘